IT201800003814A1 - FORMULATION BASED ON COFFEE POWDER - Google Patents
FORMULATION BASED ON COFFEE POWDER Download PDFInfo
- Publication number
- IT201800003814A1 IT201800003814A1 IT102018000003814A IT201800003814A IT201800003814A1 IT 201800003814 A1 IT201800003814 A1 IT 201800003814A1 IT 102018000003814 A IT102018000003814 A IT 102018000003814A IT 201800003814 A IT201800003814 A IT 201800003814A IT 201800003814 A1 IT201800003814 A1 IT 201800003814A1
- Authority
- IT
- Italy
- Prior art keywords
- coffee
- proportion
- formulation according
- dry extract
- citrulline
- Prior art date
Links
- 235000016213 coffee Nutrition 0.000 title claims description 56
- 235000013353 coffee beverage Nutrition 0.000 title claims description 56
- 239000000203 mixture Substances 0.000 title claims description 54
- 238000009472 formulation Methods 0.000 title claims description 42
- 239000000843 powder Substances 0.000 title claims description 9
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 46
- 229960002173 citrulline Drugs 0.000 claims description 23
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 16
- 235000014852 L-arginine Nutrition 0.000 claims description 16
- 229930064664 L-arginine Natural products 0.000 claims description 16
- 241000340987 Ptychopetalum olacoides Species 0.000 claims description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 11
- 240000000759 Lepidium meyenii Species 0.000 claims description 10
- 235000000421 Lepidium meyenii Nutrition 0.000 claims description 10
- 235000012902 lepidium meyenii Nutrition 0.000 claims description 10
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 10
- 244000042430 Rhodiola rosea Species 0.000 claims description 8
- 235000003713 Rhodiola rosea Nutrition 0.000 claims description 8
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 8
- 240000004160 Capsicum annuum Species 0.000 claims description 7
- 235000002567 Capsicum annuum Nutrition 0.000 claims description 7
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 7
- 244000228088 Cola acuminata Species 0.000 claims description 7
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 7
- 239000001511 capsicum annuum Substances 0.000 claims description 7
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 7
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 7
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 7
- 201000001881 impotence Diseases 0.000 claims description 7
- 229960004441 tyrosine Drugs 0.000 claims description 7
- 235000013312 flour Nutrition 0.000 claims description 6
- 235000010205 Cola acuminata Nutrition 0.000 claims description 5
- 240000000143 Turnera diffusa Species 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 5
- 235000004952 turnera diffusa Nutrition 0.000 claims description 5
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 4
- 244000062172 Turnera diffusa var. aphrodisiaca Species 0.000 claims description 4
- 229960001948 caffeine Drugs 0.000 claims description 4
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 235000021539 instant coffee Nutrition 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 229960003080 taurine Drugs 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 235000016795 Cola Nutrition 0.000 claims description 2
- 240000007049 Juglans regia Species 0.000 claims description 2
- 235000009496 Juglans regia Nutrition 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- 229930182816 L-glutamine Natural products 0.000 claims description 2
- 241000801118 Lepidium Species 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229960004203 carnitine Drugs 0.000 claims description 2
- 229940082939 cola nut extract Drugs 0.000 claims description 2
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000000378 dietary effect Effects 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 235000020234 walnut Nutrition 0.000 claims description 2
- 241000723377 Coffea Species 0.000 claims 20
- -1 caffeine Zinc oxide Chemical compound 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 10
- 239000000126 substance Substances 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 240000008574 Capsicum frutescens Species 0.000 description 3
- 239000003048 aphrodisiac agent Substances 0.000 description 3
- 230000002509 aphrodisiac effect Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000001856 erectile effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000036642 wellbeing Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 235000015438 Cola nitida Nutrition 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000035946 sexual desire Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 241000554155 Andes Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 241000220284 Crassulaceae Species 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 235000020289 caffè mocha Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000005226 corpus cavernosum Anatomy 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009986 erectile function Effects 0.000 description 1
- 235000015114 espresso Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002582 psychostimulating effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000035936 sexual power Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- OGPIIGMUPMPMNT-UHFFFAOYSA-M sodium meclofenamate (anhydrous) Chemical compound [Na+].CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C([O-])=O)=C1Cl OGPIIGMUPMPMNT-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F5/00—Coffee; Coffee substitutes; Preparations thereof
- A23F5/24—Extraction of coffee; Coffee extracts; Making instant coffee
- A23F5/36—Further treatment of dried coffee extract; Preparations produced thereby, e.g. instant coffee
- A23F5/40—Further treatment of dried coffee extract; Preparations produced thereby, e.g. instant coffee using organic additives, e.g. milk, sugar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F5/00—Coffee; Coffee substitutes; Preparations thereof
- A23F5/24—Extraction of coffee; Coffee extracts; Making instant coffee
- A23F5/28—Drying or concentrating coffee extract
- A23F5/32—Drying or concentrating coffee extract by lyophilisation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F5/00—Coffee; Coffee substitutes; Preparations thereof
- A23F5/24—Extraction of coffee; Coffee extracts; Making instant coffee
- A23F5/36—Further treatment of dried coffee extract; Preparations produced thereby, e.g. instant coffee
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Tea And Coffee (AREA)
Description
Titolo: FORMULAZIONE A BASE DI CAFFE’ IN POLVERE Title: COFFEE-BASED FORMULATION IN POWDER
Descrizione Description
Campo della tecnica dell’invenzione Field of the technique of the invention
Forma oggetto della presente invenzione una formulazione a base di caffè in polvere contenente principi attivi per il trattamento della disfunzione erettile. The subject of the present invention is a formulation based on powdered coffee containing active ingredients for the treatment of erectile dysfunction.
Stato dell’arte State of the art
Il deficit di erezione viene definito come difficoltà parziale o totale a mantenere l'erezione fino al completamento dell'attività sessuale. Le cause di questo problema sessuale possono essere fisiche e/o funzionali. Erection deficit is defined as partial or total difficulty in maintaining an erection until sexual activity is complete. The causes of this sexual problem can be physical and / or functional.
Spesso fattori di entrambi i tipi concorrono a causare e mantenere la difficoltà di erezione. Per il trattamento delle disfunzioni erettili su base fisica è necessario un trattamento delle malattie di base. Nelle forme funzionali, che non sono dovute a un evidente danno vascolare, neurologico o dismetabolico, il problema erettile è dovuto a fattori quali ansia, calo del tono dell'umore e stress cronico. La sua terapia non farmacologica consiste nell’identificazione ed il trattamento delle cause “curabili”, nel cambiamento dello stile di vita con la modifica dei fattori di rischio e nel fornire “counseling” a pazienti e partner. Often factors of both types combine to cause and maintain erection difficulties. For the treatment of erectile dysfunction on a physical basis, treatment of the underlying diseases is necessary. In functional forms, which are not due to evident vascular, neurological or dysmetabolic damage, the erectile problem is due to factors such as anxiety, decreased mood and chronic stress. Her non-drug therapy consists of identifying and treating "treatable" causes, changing lifestyle by changing risk factors and providing "counseling" to patients and partners.
La terapia farmacologica, invece, è basata sulla somministrazione di farmaci inibitori delle fosfodiesterasi (PDE5 Inhibitors) o su iniezioni intracavernose e transuretrali di prostaglandine. Circa il 20% di pazienti tuttavia non può o non vuole assumere i PDE5-inibitori. Inoltre una stragrande maggioranza di persone, anche giovani, sono affette da forme di disfunzione erettile transitorie o lievi. Drug therapy, on the other hand, is based on the administration of phosphodiesterase inhibitors (PDE5 Inhibitors) or on intracavernous and transurethral injections of prostaglandins. However, about 20% of patients are unable or unwilling to take PDE5 inhibitors. In addition, an overwhelming majority of people, even young people, are affected by transient or mild forms of erectile dysfunction.
Proprietà afrodisiache e stimolanti sono state attribuite a svariate sostanze sin dall’antichità. Un’attenta revisione degli studi clinici sulla nutraceutica mostra risultati promettenti ed incoraggianti in merito all’uso di integratori nei pazienti con calo della libido e disfunzioni sessuali. Tuttavia, è stato visto che, al di là di tali specifiche sostanze, il miglioramento del benessere psicofisico dell'uomo rappresenta il primum movens della spinta sessuale. Aphrodisiac and stimulating properties have been attributed to various substances since ancient times. A careful review of clinical trials on nutraceuticals shows promising and encouraging results regarding the use of supplements in patients with decreased libido and sexual dysfunction. However, it has been seen that, beyond these specific substances, the improvement of the psychophysical well-being of man represents the primum movens of the sexual drive.
L’obiettivo della presente invenzione è quindi quello di mettere a disposizione una formulazione che agisca in modo ampio sia con una specifica azione di miglioramento della funzionalità erettile, che nel combattere il senso di stanchezza e migliorare le normali attività quotidiane ed il benessere del paziente. The objective of the present invention is therefore to provide a formulation that acts broadly both with a specific action to improve erectile function, and in combating the sense of fatigue and improving normal daily activities and the patient's well-being.
Un ulteriore obiettivo dell’invenzione è di mettere a disposizione un integratore alimentare o una composizione dietetica per il trattamento della disfunzione erettile, in particolare nelle sue forme lievi, che risulti di piacevole assunzione. A further objective of the invention is to provide a food supplement or dietary composition for the treatment of erectile dysfunction, in particular in its mild forms, which is pleasant to take.
Sono disponibili sul mercato integratori alimentari sotto forma di compresse o fiale che tuttavia non contengono la combinazione di sostanze della presente formulazione. Tali integratori noti hanno costi elevati per il consumatore e inoltre non risultano spesso di gradevole assunzione. Food supplements are available on the market in the form of tablets or ampoules which however do not contain the combination of substances of this formulation. Such known supplements have high costs for the consumer and moreover they are often not pleasant to take.
Sommario dell’invenzione Summary of the invention
Oggetto dell’invenzione è una formulazione a base di caffè in polvere come definita nelle annesse rivendicazioni, le cui definizione formano parte integrante della presente descrizione. The subject of the invention is a formulation based on coffee powder as defined in the attached claims, the definition of which form an integral part of this description.
La formulazione dell’invenzione non altera il gusto del caffè anche se contiene dei principi che contribuiscono a migliorare il deficit erettile ed il benessere psicofisico in generale. The formulation of the invention does not alter the taste of coffee even though it contains principles that help improve erectile deficit and psychophysical well-being in general.
Gli ingredienti usati nella formulazione inoltre non comportano rischi legati alla loro assunzione. The ingredients used in the formulation also do not involve risks associated with their intake.
Ulteriori caratteristiche e vantaggi del processo secondo l’invenzione risulteranno dalla descrizione di seguito riportata di esempi preferiti di realizzazione, dati a titolo indicativo e non limitativo. Further features and advantages of the process according to the invention will result from the following description of preferred embodiment examples, given for indicative and non-limiting purposes.
Descrizione dettagliata dell’invenzione Detailed description of the invention
La presente invenzione riguarda una formulazione a base di caffè comprendente una sostanza capace di indurre la biosintesi di monossido d’azoto (NO), detta anche precursore dell’ossido nitrico. Tale sostanza precursore dell’ossido nitrico è preferibilmente L-citrullina e/o L-arginina, più preferibilmente L-citrullina o una miscela L-citrullina e L-arginina. The present invention relates to a coffee-based formulation comprising a substance capable of inducing the biosynthesis of nitrogen monoxide (NO), also called nitric oxide precursor. This nitric oxide precursor substance is preferably L-citrulline and / or L-arginine, more preferably L-citrulline or a mixture of L-citrulline and L-arginine.
L’associazione tra caffè ed L-citrullina ha un effetto sinergico. La caffeina agisce da blando inibitore aspecifico della fosfodiesterasi e con la sua azione favorisce l'afflusso del sangue nei corpi cavernosi del pene incitando così l'erezione. Il suo effetto è potenziato dalla L-citrullina o dalla L-arginina o da una loro combinazione, grazie all’azione del monossido d’azoto che funge da vasodilatatore. The association between coffee and L-citrulline has a synergistic effect. Caffeine acts as a mild non-specific inhibitor of phosphodiesterase and with its action promotes the flow of blood into the corpora cavernosa of the penis, thus inducing an erection. Its effect is enhanced by L-citrulline or L-arginine or a combination thereof, thanks to the action of nitrogen monoxide which acts as a vasodilator.
In generale, la proporzione tra L-citrullina e caffè è compresa tra 25:100 e 50:100. In general, the ratio of L-citrulline to coffee is between 25: 100 and 50: 100.
Il termine “caffè” utilizzato nella presente invenzione indica caffè in forma solida, preferibilmente scelto tra caffè in polvere, caffè liofilizzato e loro miscele. The term "coffee" used in the present invention indicates coffee in solid form, preferably selected from ground coffee, freeze-dried coffee and their blends.
In certe forme di realizzazione, la formulazione dell’invenzione comprende ulteriormente L-arginina. In tali forme di realizzazione la proporzione tra L-arginina e caffè è preferibilmente compresa tra 2:100 e 3:100. In certain embodiments, the formulation of the invention further comprises L-arginine. In such embodiments the proportion between L-arginine and coffee is preferably between 2: 100 and 3: 100.
In certe forme di realizzazione, la formulazione comprende un estratto secco di radice di Muira Puama (Lirisoma ovata). La Muira Puama, anche nota come albero della potenza, è utilizzabile per le sue proprietà afrodisiache e rinvigorenti e fornisce quindi un effetto sinergico in combinazione con caffè e L-citrullina. Studi clinici per indagarne le ripercussioni sugli aspetti fisici e psicologici riconducibili alla sfera sessuale hanno dimostrato che la Muira Puama è efficace nel ripristinare il desiderio sessuale nel 60% dei pazienti, con un effetto positivo nel trattamento della disfunzione erettile nel 53% dei casi (Waynberg (1994) Am J Nat Med 1:8-9). In tali forme di realizzazione, la proporzione tra estratto di Muira Puama e caffè è preferibilmente compresa tra 0,5:100 e 1,5:100. In certain embodiments, the formulation comprises a dry extract of Muira Puama root (Lirisoma ovata). Muira Puama, also known as the tree of potency, is usable for its aphrodisiac and invigorating properties and therefore provides a synergistic effect in combination with coffee and L-citrulline. Clinical studies to investigate the repercussions on the physical and psychological aspects attributable to the sexual sphere have shown that Muira Puama is effective in restoring sexual desire in 60% of patients, with a positive effect in the treatment of erectile dysfunction in 53% of cases (Waynberg (1994) Am J Nat Med 1: 8-9). In such embodiments, the proportion between Muira Puama extract and coffee is preferably between 0.5: 100 and 1.5: 100.
In certe forme di realizzazione, la formulazione contiene farina di radice essiccata di Maca (Lepidium meyeni). La Maca è una pianta che cresce quasi esclusivamente nelle Ande. Nella cultura dei popoli andini è sempre stata utilizzata per incrementare il desiderio sessuale e la fertilità delle coppie ed è in generale un rinvigorente grazie alla miscela di sostanze nutritive che contiene, per cui fornisce un effetto sinergico in combinazione con caffè e L-citrullina. Studi hanno dimostrato la capacità della Maca di migliorare le performance sessuali. In tali forme di realizzazione, la proporzione tra farina di Maca e caffè è preferibilmente compresa tra 12:100 e 18:100. In certain embodiments, the formulation contains dried Maca root flour (Lepidium meyeni). Maca is a plant that grows almost exclusively in the Andes. In the culture of the Andean peoples it has always been used to increase sexual desire and fertility of couples and is in general an invigorating thanks to the mixture of nutrients it contains, for which it provides a synergistic effect in combination with coffee and L-citrulline. Studies have shown Maca's ability to improve sexual performance. In such embodiments, the proportion between Maca flour and coffee is preferably between 12: 100 and 18: 100.
In certe forme di realizzazione, la formulazione secondo l’invenzione è sotto forma di dosi singole per la preparazione di un infuso di caffè. In certain embodiments, the formulation according to the invention is in the form of single doses for the preparation of a coffee infusion.
Una dose singola comprende caffè e L-citrullina nei seguenti quantitativi: A single serving includes coffee and L-citrulline in the following quantities:
3,5-6 g caffè 3.5-6 g coffee
1-3 g L-citrullina. 1-3 g L-citrulline.
Una diversa dose singola di formulazione comprende caffè, L-citrullina e L-arginina nei seguenti quantitativi: A different single dose formulation includes coffee, L-citrulline and L-arginine in the following amounts:
3,5-6 g caffè 3.5-6 g coffee
1-3 g L-citrullina 1-3 g L-citrulline
90-150 mg L-arginina. 90-150 mg L-arginine.
Ancora un’altra dose singola della formulazione comprende almeno le seguenti componenti: Yet another single dose of the formulation includes at least the following components:
3,5-6 g caffè 3.5-6 g coffee
1-3 g L-citrullina 1-3 g L-citrulline
25-60 mg estratto secco di radici di Muira Puama e, opzionalmente 25-60 mg dry extract of Muira Puama roots and optionally
90-150 mg L-arginina. 90-150 mg L-arginine.
Un’ulteriore dose singola della formulazione comprende almeno le seguenti componenti: An additional single dose of the formulation includes at least the following components:
3,5-6 g caffè 3.5-6 g coffee
1-3 g L-citrullina 1-3 g L-citrulline
500-900 mg farina di radici essiccate di Maca, opzionalmente 500-900 mg dried Maca root flour, optionally
90-150 mg L-arginina, e 90-150 mg L-arginine, e
opzionalmente optionally
25-60 mg estratto secco di radici di Muira Puama. La formulazione dell’invenzione può inoltre comprendere ulteriori componenti, preferibilmente scelte tra tirosina, taurina, estratto secco di noce di Cola acuminata, estratto secco di Damiana (Turnera aphrodisiaca), estratto secco di Rhodiola rosea, Capsicum annuum, coenzima Q10 e loro miscele. 25-60 mg dry extract of Muira Puama roots. The formulation of the invention may also include further components, preferably selected from tyrosine, taurine, dry extract of kola acuminata, dry extract of Damiana (Turnera aphrodisiaca), dry extract of Rhodiola rosea, Capsicum annuum, coenzyme Q10 and their mixtures.
La tirosina è l'amminoacido di partenza per la sintesi di importanti neurotrasmettitori, come la dopamina, l'adrenalina e la noradrenalina. Queste ultime due sostanze sono importantissime per il processo di adattamento a stress psicofisici intensi ed improvvisi. Tyrosine is the starting amino acid for the synthesis of important neurotransmitters, such as dopamine, adrenaline and noradrenaline. These last two substances are very important for the process of adaptation to intense and sudden psychophysical stress.
La taurina è un aminoacido che grazie alle sue proprietà antiossidanti viene raccomandato ai soggetti sottoposti ad intenso allenamento e favorisce il recupero fisico dopo un intenso sforzo riducendo il danno muscolare e lo stress ossidativo. Essa migliora il metabolismo dei lipidi e degli zuccheri a livello epatico; favorisce l'escrezione renale di sostanze tossiche; favorisce la contrattilità della muscolatura scheletrica e del cuore aumentandone così la gittata cardiaca. Viene pertanto consigliata per aumentare le performance atletiche. Taurine is an amino acid which, thanks to its antioxidant properties, is recommended to subjects subjected to intense training and promotes physical recovery after intense effort by reducing muscle damage and oxidative stress. It improves the metabolism of lipids and sugars in the liver; promotes the renal excretion of toxic substances; it favors the contractility of the skeletal muscles and of the heart, thus increasing the cardiac output. It is therefore recommended to increase athletic performance.
Le noci di Cola sono utilizzate da moltissimo tempo per le loro proprietà terapeutiche come stimolanti del sistema nervoso, con azione antidepressiva. Esse si sono dimostrate utili nel trattamento di stati di esaurimento, anoressia mentale, attacchi di malinconia, e nelle persone debilitate e convalescenti. Kola nuts have been used for a very long time for their therapeutic properties as stimulants of the nervous system, with an antidepressant action. They have been shown to be useful in the treatment of states of exhaustion, mental anorexia, bouts of melancholy, and in the debilitated and convalescent.
Alla Damiana fin dall'antichità sono state attribuite proprietà afrodisiache e psicostimolanti. Da varie fonti emerge che si tratta di un rimedio naturale piuttosto efficace contro i deficit erettivi, capace di incrementare il volume spermatico ed è da tempo approvato dalla farmacopea statunitense. Damiana has been attributed aphrodisiac and psychostimulating properties since ancient times. From various sources it emerges that it is a rather effective natural remedy against erectile deficits, capable of increasing sperm volume and has long been approved by the US pharmacopoeia.
La Rhodiola rosea è una pianta medicinale appartenente alla famiglia delle Crassulaceae. Tra i principi attivi della Rhodiola si annovera il salidrosalide. Esso stimola la produzione di serotonina, adrenalina e dopamina, migliorando il tono dell’umore e agendo positivamente sulle funzioni metaboliche di cuore, fegato e muscoli. Gli acidi organici e i flavonoidi contenuti nella Rhodiola rosea, invece, ne determinano le sue proprietà antiossidanti. Rhodiola rosea is a medicinal plant belonging to the Crassulaceae family. Salidrosalide is one of the active ingredients of Rhodiola. It stimulates the production of serotonin, adrenaline and dopamine, improving mood and acting positively on the metabolic functions of the heart, liver and muscles. The organic acids and flavonoids contained in Rhodiola rosea, on the other hand, determine its antioxidant properties.
Il Capsicum Annuum è una varietà di peperoncino. Il peperoncino ha un forte potere anti ossidante. Le proprietà vasodilatatrici e anticolesterolo, insieme con l’azione della vitamina PP che rende elastici i capillari, e la vitamina E che aumenta l’ossigenazione del sangue, rendono il peperoncino utile nella prevenzione e nella cura dell’aterosclerosi. Capsicum Annuum is a variety of chilli. Chilli has a strong antioxidant power. The vasodilating and anti-cholesterol properties, together with the action of vitamin PP which makes capillaries elastic, and vitamin E which increases blood oxygenation, make chilli pepper useful in the prevention and treatment of atherosclerosis.
Il coenzima Q10 è un potente antiossidante che si trova in quasi tutte le cellule del corpo. Il suo ruolo principale è quello di convertire gli alimenti in energia disponibile per l’organismo. Coenzyme Q10 is a powerful antioxidant found in almost all cells in the body. Its main role is to convert food into energy available for the body.
In generale, quando presente, la proporzione tra L-tirosina e caffè è compresa tra 4:100 e 15:100. In general, when present, the proportion between L-tyrosine and coffee is between 4: 100 and 15: 100.
In generale, quando presente, la proporzione tra L-taurina e caffè è compresa tra 4:100 e 9:100. In general, when present, the proportion between L-taurine and coffee is between 4: 100 and 9: 100.
In generale, quando presente, la proporzione tra estratto secco di noce di Cola (titolato al 10% in caffeina) e caffè è compresa tra 0,5:100 e 1:100. In general, when present, the proportion between dry Cola nut extract (titrated to 10% caffeine) and coffee is between 0.5: 100 and 1: 100.
In generale, quando presente, la proporzione tra estratto secco di Damiana e caffè è compresa tra 0,5:100 e 1:100. In general, when present, the proportion between Damiana dry extract and coffee is between 0.5: 100 and 1: 100.
In generale, quando presente, la proporzione tra estratto secco di Rhodiola rosea e caffè è compresa tra 4:100 e 8:100. In general, when present, the ratio between dry extract of Rhodiola rosea and coffee is between 4: 100 and 8: 100.
In generale, quando presente, la proporzione tra Capsicum annuum e caffè è compresa tra 0,1:100 e 0,12:100. In general, when present, the proportion between Capsicum annuum and coffee is between 0.1: 100 and 0.12: 100.
In generale, quando presente, la proporzione tra coenzima Q10 e caffè è compresa tra 0,08:100 e 0,1:100. In general, when present, the proportion between coenzyme Q10 and coffee is between 0.08: 100 and 0.1: 100.
In una forma di realizzazione particolarmente preferita, la formulazione dell’invenzione è sotto forma di una dose singola per un infuso di caffè ed ha la seguente composizione: In a particularly preferred embodiment, the formulation of the invention is in the form of a single dose for a coffee infusion and has the following composition:
Caffè 3,5-6 g Coffee 3.5-6 g
L-citrullina 1-3 g L-citrulline 1-3 g
L-arginina 90-150 mg L-arginine 90-150 mg
L-tirosina 150-900 mg L-tyrosine 150-900 mg
L-taurina 150-500mg L-taurine 150-500mg
Muira Puama (lirisoma ovata) 25-60 mg Muira Puama (lyrisoma ovata) 25-60 mg
radice estratto secco root dry extract
Cola (cola acuminata) noce 20-50 mg Cola (cola acuminata) walnut 20-50 mg
estratto secco titolato al 10% dry extract titrated at 10%
in caffeina in caffeine
Zinco ossido 3-5 mg Zinc oxide 3-5 mg
L-glutammina Carnitina 1-3 mg L-glutamine Carnitine 1-3 mg
Turnera Aphrodisiaca 20-50 mg Turnera Aphrodisiaca 20-50 mg
Rhodiola rosea 150-450mg Rhodiola rosea 150-450mg
Coenzima Q10 3-5 mg Coenzyme Q10 3-5 mg
Calcio 110-130 mg Calcium 110-130 mg
Magnesio 110-130 mg Magnesium 110-130 mg
Maca 500-900 mg Maca 500-900 mg
Potassio 140-160 mg Potassium 140-160 mg
Capsicum Annuum 4-7 mg Capsicum Annuum 4-7 mg
La formulazione dell’invenzione può essere preparata miscelando alcune o tutte le componenti sopra descritte, sotto forma di polveri di granulometria adatta per la preparazione di un infuso di caffè per l’utilizzo, a seconda del caso, con caffettiere del tipo moka o napoletana o per la preparazione di caffè espresso. The formulation of the invention can be prepared by mixing some or all of the components described above, in the form of powders of particle size suitable for the preparation of a coffee infusion for use, depending on the case, with mocha or Neapolitan coffee makers or for the preparation of espresso coffee.
La L-citrullina ha un sapore amaro pronunciato, per cui la formulazione dell’invenzione potrà comprendere dei mascheranti del sapore amaro, del tipo normalmente utilizzato in preparazioni farmaceutiche. L-citrulline has a pronounced bitter taste, so the formulation of the invention may include bitter taste masks, of the type normally used in pharmaceutical preparations.
La formulazione a base di polvere di caffè potrà essere fornita come tale oppure potrà presentarsi in capsule o cialde monodose di tipo convenzionale, nelle quantità normalmente utilizzate per tali applicazioni (ad esempio tra 5 e 7 grammi di formulazione per cialda o capsula). The coffee powder-based formulation can be supplied as such or can be presented in conventional single-dose capsules or pods, in the quantities normally used for such applications (for example between 5 and 7 grams of formulation per pod or capsule).
In una diversa forma di realizzazione, la formulazione dell’invenzione si presenterà sotto forma di caffè istantaneo o solubile. In questo caso, la formulazione dell’invenzione verrà utilizzata per preparare un infuso, che verrà concentrato, liofilizzato e granulato per ottenere il prodotto finito, secondo tecniche convenzionali. In a different embodiment, the formulation of the invention will come in the form of instant or soluble coffee. In this case, the formulation of the invention will be used to prepare an infusion, which will be concentrated, freeze-dried and granulated to obtain the finished product, according to conventional techniques.
La formulazione dell’invenzione può essere un alimento dietetico o un integratore alimentare. The formulation of the invention can be a dietary food or a food supplement.
Un ulteriore oggetto dell’invenzione è la formulazione dell’invenzione per l’uso nel trattamento della disfunzione erettile nell’uomo. A further object of the invention is the formulation of the invention for use in the treatment of erectile dysfunction in men.
E’ evidente che sono state descritte solo alcune forme particolari di realizzazione della presente invenzione, cui l’esperto dell’arte sarà in grado di apportare tutte quelle modifiche necessarie per il suo adattamento a particolari applicazioni, senza peraltro discostarsi dall’ambito di protezione della presente invenzione. It is evident that only some particular embodiments of the present invention have been described, to which the skilled in the art will be able to make all those modifications necessary for its adaptation to particular applications, without however departing from the scope of protection of the present invention.
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102018000003814A IT201800003814A1 (en) | 2018-03-21 | 2018-03-21 | FORMULATION BASED ON COFFEE POWDER |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102018000003814A IT201800003814A1 (en) | 2018-03-21 | 2018-03-21 | FORMULATION BASED ON COFFEE POWDER |
Publications (1)
Publication Number | Publication Date |
---|---|
IT201800003814A1 true IT201800003814A1 (en) | 2019-09-21 |
Family
ID=62530486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IT102018000003814A IT201800003814A1 (en) | 2018-03-21 | 2018-03-21 | FORMULATION BASED ON COFFEE POWDER |
Country Status (1)
Country | Link |
---|---|
IT (1) | IT201800003814A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT202100031175A1 (en) * | 2021-12-13 | 2023-06-13 | Anvest Group S R L | COMPOSITION FOR THE TREATMENT OF ERECTILE DYSFUNCTION |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060110478A1 (en) * | 2004-11-22 | 2006-05-25 | Mccleary Edward L | Delivery system and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction |
DE102008021586A1 (en) * | 2008-04-30 | 2009-11-12 | Metsäla, Pertti | Dietary composition, useful for producing sports energy drink, comprises roasted coffee component, food component comprising e.g. carbohydrates and chlorogenic acid, vasoactive component, amino acid component and fruit component |
CN102258106A (en) * | 2010-05-26 | 2011-11-30 | 金圣凯 | Coffee for improving male function |
US20120121740A1 (en) * | 2010-10-19 | 2012-05-17 | K.L.R.M., Llc | Compositions and methods for treating, inhibiting the onset, and slowing the progression of erectile dysfunction including naturally occurring age related erectile dysfunction |
US20160026673A1 (en) * | 2014-07-25 | 2016-01-28 | Linkedin Corporation | Ensuring consistency of derived data in a distributed storage system |
US20160303176A1 (en) * | 2015-04-15 | 2016-10-20 | Erroll J. Bailey | Nutritional supplement |
US20160311607A1 (en) * | 2013-07-03 | 2016-10-27 | Mars, Incorporated | Beverage preparation capsules for delivery of functional ingredients |
-
2018
- 2018-03-21 IT IT102018000003814A patent/IT201800003814A1/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060110478A1 (en) * | 2004-11-22 | 2006-05-25 | Mccleary Edward L | Delivery system and method for supporting and promoting healthy sexual function and prevention and treatment of sexual dysfunction |
DE102008021586A1 (en) * | 2008-04-30 | 2009-11-12 | Metsäla, Pertti | Dietary composition, useful for producing sports energy drink, comprises roasted coffee component, food component comprising e.g. carbohydrates and chlorogenic acid, vasoactive component, amino acid component and fruit component |
CN102258106A (en) * | 2010-05-26 | 2011-11-30 | 金圣凯 | Coffee for improving male function |
US20120121740A1 (en) * | 2010-10-19 | 2012-05-17 | K.L.R.M., Llc | Compositions and methods for treating, inhibiting the onset, and slowing the progression of erectile dysfunction including naturally occurring age related erectile dysfunction |
US20160311607A1 (en) * | 2013-07-03 | 2016-10-27 | Mars, Incorporated | Beverage preparation capsules for delivery of functional ingredients |
US20160026673A1 (en) * | 2014-07-25 | 2016-01-28 | Linkedin Corporation | Ensuring consistency of derived data in a distributed storage system |
US20160303176A1 (en) * | 2015-04-15 | 2016-10-20 | Erroll J. Bailey | Nutritional supplement |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT202100031175A1 (en) * | 2021-12-13 | 2023-06-13 | Anvest Group S R L | COMPOSITION FOR THE TREATMENT OF ERECTILE DYSFUNCTION |
EP4193848A1 (en) * | 2021-12-13 | 2023-06-14 | Anvest Group S.r.l. | Composition for use in the treatment of erectile dysfunction |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8491943B2 (en) | Method and composition for improved anabolism | |
US20210220422A1 (en) | Dietary supplement compositions and methods | |
US20190117555A1 (en) | Sublingual compositions comprising natural extracts and uses thereof | |
US20040234544A1 (en) | Formulation containing (lyso-)phosphatidylserine for the prevention and treatment of stress states in warm blooded animals | |
HRP20121072T1 (en) | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring | |
TW200410680A (en) | Nutritiona compositions | |
US20140134281A1 (en) | Functional formulation | |
ES2462553A1 (en) | Composition for improvement of sexual well-being (Machine-translation by Google Translate, not legally binding) | |
US20160303177A1 (en) | Nutritional supplement | |
JP4904795B2 (en) | Fatigue improver composition | |
WO2018112475A1 (en) | Energy compositions and methods | |
EP3086798B1 (en) | Formulations based on astragaloside iv or extracts containing it for the prevention and treatment of insomnia and jet-lag-related disorders | |
US7943183B2 (en) | Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition | |
JP2007161675A (en) | Fatigue-improving internal medicine | |
US20150157672A1 (en) | Kits and methods for sustained weight loss | |
IT201800003814A1 (en) | FORMULATION BASED ON COFFEE POWDER | |
TWI793058B (en) | Disease Behavior Symptom Improver | |
Yavuz et al. | Herbs potentially enhancing sports performance. | |
US20190160126A1 (en) | Compositions and methods for treating reproductive indicators symptomatic of male infertility | |
JP2007161643A (en) | Prophylactic or ameliorating agent for pms | |
WO2017048882A1 (en) | Compositions for regulation and control of appetite | |
US20130280354A1 (en) | Composition and Method for Using Sage | |
RU2189243C1 (en) | Compositions "ginrosin" showing general tonic and adaptogenic effect | |
ES2587932T3 (en) | Compositions for use in relieving symptoms associated with premenstrual syndrome and premenstrual dysphoric disorder | |
JP7460327B2 (en) | Oral Compositions |